Take your gMG patients from getting by to getting better

Even stable patients may be struggling with symptoms. Taking a different approach, including using the MG-ADL scale to monitor symptoms, aligning on treatment goals with patients, and talking to them about using targeted therapies* sooner in conjunction with traditional treatments, may help raise the bar on outcomes to help move your patients forward.^1-3

EXPLORE DIFFERENT APPROACHES

Patient portrayal

The image above is a partial depiction of the MG-ADL scale, which evaluates 8 signs and symptoms, each ranging from a score of 0-3. This is a portrayal of one of those functions: ability to arise from a chair.

*Targeted therapies are treatments that target the underlying pathophysiological pathways of the disease.⁴

gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.

The impact of gMG^5†

57^%

of patients have difficulty performing basic self-care activities such as bathing, dressing, grooming, eating, and using the bathroom

89^%

have experienced an inability to participate in hobbies, sports, or social activities

96^%

reported impacts on social functioning including difficulty dating and feeling uncomfortable or anxious in social situations

EXPLORE THE IMPACT OF gMG

^†Data collected from a qualitative, cross-sectional, non-interventional study in 28 people who reported receiving at least one treatment for gMG. Eligible participants were US residents, ≥18 years old, and comfortable reading and communicating in English. Study excluded people with only ocular disease to better understand the breadth of MG symptoms that affect all muscle groups.

gMG=generalized myasthenia gravis; MG=myasthenia gravis.

Dive into the pathophysiology of gMG^6-10

gMG is a chronic, debilitating, IgG-mediated autoimmune disease that causes intense fluctuating muscle weakness that can result in:

Impaired
mobility

Impaired
speech

Impaired
swallowing

Impaired
vision

Muscle
fatigability

LEARN ABOUT gMG

gMG=generalized myasthenia gravis; IgG=immunoglobulin G.

Utilize the MG-ADL scale in clinical practice

The MG-ADL scale is an easy-to-use tool that assesses 8 functions typically affected in gMG and allows you to quantify your patients' symptoms. Each function is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.^1,11,12‡

USING THE MG-ADL SCALE

^‡Data was collected from 45 patients who were starting immunomodulatory treatment for MG for the first time who did not have other medical conditions that would interfere with treatment with prednisone or IVIG or that the investigator considered important. Pregnant or breastfeeding individuals were excluded.

gMG=generalized myasthenia gravis; IVIG=intravenous immunoglobulin; MG=myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.

Discover an FDA-approved gMG treatment option

LEARN MORE

Hear from experts

Srikanth Muppidi, MD

The MG-ADL scale as a clinical tool: The power of patient perspective

James F. Howard Jr, MD

How to administer and use the MG-ADL scale in clinical practice

Jeffrey Rosenfeld, MD, PhD

Striving for Minimal Symptom Expression as a Treatment Goal in Myasthenia Gravis

Frederic Nguyen, MD and Sami Khella, MD

Shared Decision-Making in Setting Treatment Goals in Myasthenia Gravis

ADDITIONAL RESOURCES

gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.

Connect with us

Stay on top of the latest developments in gMG management by gaining access to additional resources as they're released.

References: 1. Muppidi S et al. Muscle Nerve. 2022;65:630-639. doi:10.1002/mus.27476 2. Mantegazza R, Antozzi C. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00981 3. Nair SS, Jacob S. Immunotargets Ther. 2023;12:25-45. doi:10.2147/itt.s377056 4. Sánchez-Tejerina et al. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394 5. Jackson K et al. Neurol Ther. 2023;12(1):107-128. doi:10.1007/s40120-022-00408-x 6. Gilhus NE et al. Nat Rev Neurol. 2016;12(5):259-268. doi:10.1038/nrneurol.2016.44 7. Gilhus NE. N Engl J Med. 2016;375(26):2570-2581. doi:10.1056/NEJMra1602678 8. Rødgaard A et al. Clin Exp Immunol. 1987;67(1):82-88. 9. Behin A, Le Panse R. J Neuromuscul Dis. 2018;5(3):265-277. doi:10.3233/JND-170294 10. Twork S et al. Health Qual Life Outcomes. 2010;8:129. doi:10.1186/1477-7525-8-129 11. Wolfe GI et al. Neurology. 1999;52(7):1487-1489. doi:10.1212/wnl.52.7.1487 12. Diez Porras L et al. J Clin Med. 2022;11(8):2189. doi:10.3390/jcm11082189